PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS

The phase 1/2 STARTRK-NG trial is evaluating entrectinib, a CNS-penetrant oral inhibitor of TRK, ROS1 and ALK tyrosine kinases, in children with solid tumors, including primary CNS tumors. Eligible patients are ≤22y with recurrent/refractory solid tumors. The recommended dose was determined in all-c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Robinson, Giles, Desai, Ami, Gauvain, Karen, Basu, Ellen, Dorris, Kathleen, Maese, Luke, Sabnis, Amit, Foster, Jennifer, Shusterman, Suzanne, Yoon, Janet, Weiss, Brian, Abdelbaki, Mohamed, Farid-Kapadia, Mufiza, Meneses-Lorente, Georgina, Cardenas, Alison, Hutchinson, Katherine, Bergthold, Guillaume, Chow Maneval, Edna, Fox, Elizabeth, Gajjar, Amar
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Pediatric Clinical Trials
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847414/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.774
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky